GlaxoSmithKline has racked up a slate of drug approvals this year, an impressive accomplishment for a company that had to endure a lengthy fallow period in R&D after it reorganized its extensive research operations.
When a patient succumbs to a heart attack, the cardiologist places a stent to open the offending artery. But adding multiple, preventive stents seems to produce better outcomes than just one, U.K. researchers conclude in a new study.
An Abbott Diagnostics assay wowed researchers by identifying far more female patients likely to suffer heart attacks than current technology allows.
Scientists think they have a litmus test for acute coronary syndrome that may also solve emergency room overcrowding. Researchers believe they've found a biomarker that can instantly determine which patients with chest pain are actually at risk of heart attack and which can be safely discharged.
With flu vaccines arriving in pharmacies and National Immunization Awareness Month well under way, the benefits of vaccines have been well documented in recent weeks. And a new study shows flu vaccines may provide even more benefits than originally thought.
An investigative team of heart experts has tracked down a pair of biomarkers they say can flag people who are at risk of having "silent strokes," asymptomatic events that can quietly damage the brain and leave them threatened by even worse incidents of heart and vascular disease.
Another team of researchers is tackling the task of developing a blood test designed to predict a patient's likelihood of suffering a heart attack. And they've zeroed on three promising biomarkers to help get the job done.
Pozen submitted an application with the FDA for a tablet that combines the gastrointestinal drug omeprazole and an asipirin core coated with a pH-sensitive material.
In the fall of 2011, CardioKinetix raised the first half of its $44 million Series E round. Now, the California company and 2012 Fierce 15 winner has nailed down the difference, a $23 million second tranche. Plans call for putting the money to work immediately in a variety of ways to advance the company's second-generation Parachute Ventricular Partitioning Device for heart failure.
Devicemakers have demonstrated that renal denervation can make a substantial difference in the lives of hypertension sufferers, but now St. Jude Medical is kicking off a landmark study to see if the treatment can also reduce the risk of heart attack, stroke and death.